Who Supplies Carfilzomib to India from IRELAND

To import finished pharmaceutical formulations containing Carfilzomib into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organisation (CDSCO). The application process involves submitting Form 40/41 to CDSCO, along with necessary documents such as the Free Sale Certificate, Good Manufacturing Practice (GMP) certificate, and Certificate of Pharmaceutical Product (CoPP). The registration certificate is valid for three years from the date of issue. The Import License is also valid for three years and is required for each consignment. The timeline for obtaining these approvals can vary but typically ranges from six months to one year, depending on the completeness of the application and the regulatory review process. For formulations under HS Code 30049049, compliance with the Drugs and Cosmetics Act, 1940, and the associated rules is mandatory.

Imported pharmaceutical formulations containing Carfilzomib must undergo quality testing at CDSCO-approved laboratories in India. The importer is required to submit samples from each batch for analysis, including the Certificate of Analysis (CoA) from the exporting country’s laboratory. Stability data, adhering to International Council for Harmonisation (ICH) guidelines for Zone IV, is also necessary. The formulations must meet the standards set by the Indian Pharmacopoeia. Port inspection by customs drug inspectors is conducted to ensure compliance with these requirements. The batch testing process can take several weeks, and if a batch fails to meet the required standards, it may be rejected, leading to delays and potential financial losses.

In April 2025, the CDSCO introduced new regulations mandating import registration and licenses for all pharmaceutical imports, including finished formulations containing Carfilzomib. This measure aims to prevent the sale of unapproved or illegal medicines in the Indian market. The policy emphasizes the need for compliance with the Drugs and Cosmetics Act, 1940, and associated rules. Additionally, the Production Linked Incentive (PLI) scheme, implemented in 2020, has impacted the import of finished formulations by encouraging domestic manufacturing and reducing dependency on imports. These regulatory updates are part of India's broader efforts to enhance the quality and self-reliance of its pharmaceutical industry.

India imports finished pharmaceutical formulations containing Carfilzomib primarily due to the unavailability of certain patented or branded formulations and specialized dosage forms domestically. The domestic capacity to produce these formulations is limited, leading to a dependency on imports to meet patient needs. The market size for Carfilzomib formulations in India is substantial, with a growing number of patients requiring treatment for multiple myeloma and other related conditions. The importation of these formulations ensures access to the latest treatment options and supports the healthcare system in providing comprehensive care.

The import duty structure for finished pharmaceutical formulations containing Carfilzomib under HS Code 30049049 includes a Basic Customs Duty (BCD) of 10%. A Social Welfare Surcharge (SWS) of 10% is applied on the BCD, resulting in an effective duty of 11%. Integrated Goods and Services Tax (IGST) is levied as per the prevailing rates, calculated on the assessable value plus applicable customs duties. Exemptions may apply under specific trade agreements or government notifications. The total landed duty percentage varies based on the CIF (Cost, Insurance, and Freight) value and the applicable IGST rate. Importers should consult the latest Customs Tariff Schedule and government notifications for precise duty calculations.

India sources finished pharmaceutical formulations containing Carfilzomib from Ireland due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and the availability of patented formulations not produced domestically. Ireland's pharmaceutical industry is known for its high-quality products and compliance with Good Manufacturing Practice (GMP) guidelines. While other suppliers such as China, Germany, and the United States also export Carfilzomib formulations to India, Ireland's competitive advantage lies in its established reputation for quality and reliability. Ireland's share in the Indian market for Carfilzomib formulations is significant, reflecting the trust and preference Indian importers have for Irish pharmaceutical products.

India imports finished pharmaceutical formulations containing Carfilzomib from Ireland due to the unavailability of certain patented or branded formulations and specialized dosage forms domestically. The domestic manufacturing capacity for these formulations is limited, leading to a dependency on imports to meet patient needs. Ireland's pharmaceutical industry is known for its high-quality products and adherence to international standards, making it a preferred source for these specialized formulations.

When compared to other origins such as China, Germany, and the United States, Ireland offers a competitive advantage in terms of product quality, regulatory compliance, and reliability. While other countries may offer lower prices, Ireland's adherence to Good Manufacturing Practice (GMP) guidelines and its established reputation in the pharmaceutical industry make it a preferred choice for importing finished formulations containing Carfilzomib.

Indian importers face several supply chain risks when importing finished pharmaceutical formulations containing Carfilzomib from Ireland. These include single-source risk, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks